CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...

ImmunityBio's stock has risen sharply this year. Read more on whether investors should look closely at shares or avoid the ...

Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet ...

Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on ONCY stock, giving a Buy rating yesterday. John Newman has given ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

HALIX B.V., a leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of complex therapeutic antibodies (proteins) and viral products, is ...

Kleo, a prominent provider of EPOS systems and self-ordering kiosks, is excited to announce a new partnership with Londis, one of the UK's most recognised convenience store chains. This collaboration ...

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes ...